FDA Publishes Guidance on Clinical Trials
At the beginning of August, the FDA released a guideline on monitoring of clinical trials. This document is the final version of a draft dated August 2011 in which a few comments have been integrated. The guideline includes for example more details about the performance of risk-based monitoring and monitoring technique. The document entitled "Guidance for Industry Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring" has a pretty wide scope and applies to both medicinal products and medical devices. With this guideline, the FDA aims to support the sponsors of clinical trials with medicinal products (chemical and biological APIs), and/ or with medical devices (Investigational Devices Exemption (IDE) studies) and/ or combination products. Patient safety is, of course, the main concern. The quality of data is also addressed. To ensure it, the sponsor has to focus - with his/ her monitoring activities - on the main aspects of the studies and the related reports. In a word, he/ she has to choose a risk-based approach. The 22-page guideline tries to describe these two main objectives.
The guideline can be found here.
Related GMP News
18.01.2024Notified Body Survey on Certificates and Applications under the Medical Devices/IVD Regulation
18.01.2024Update of the EMA Q&A document on Combination Products
18.01.2024MDCG Guidance on the Responsible Person according to Article 15 MDR Updated
07.11.2023Harmonisation Efforts of the CDRH
07.11.2023Medical Devices Warning Letter Statistics for Fiscal Year 2023
07.11.2023FDA Publishes Lists of Planned Medical Device Guidances for Fiscal Year 2024